These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 22951636)

  • 1. HIV infection and glycemic response to newly initiated diabetic medical therapy.
    Han JH; Crane HM; Bellamy SL; Frank I; Cardillo S; Bisson GP;
    AIDS; 2012 Oct; 26(16):2087-95. PubMed ID: 22951636
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparative Effectiveness of Diabetic Oral Medications Among HIV-Infected and HIV-Uninfected Veterans.
    Han JH; Gordon K; Womack JA; Gibert CL; Leaf DA; Rimland D; Rodriguez-Barradas MC; Bisson GP
    Diabetes Care; 2017 Feb; 40(2):218-225. PubMed ID: 27634393
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Short-term intensive insulin therapy could be the preferred option for new onset Type 2 diabetes mellitus patients with HbA1c > 9.
    Weng J
    J Diabetes; 2017 Oct; 9(10):890-893. PubMed ID: 28661564
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Determinants of Glycemic Response to Add-On Therapy with a Dipeptidyl Peptidase-4 Inhibitor: A Retrospective Cohort Study Using a United Kingdom Primary Care Database.
    Mamza J; Mehta R; Donnelly R; Idris I
    Diabetes Technol Ther; 2016 Feb; 18(2):85-92. PubMed ID: 26752504
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Real-World Glycemic Control from GLP-1RA Therapy with and Without Concurrent Insulin in Patients with Type 2 Diabetes.
    Singhal M; Unni S; Schauerhamer M; Nguyen H; Hurd J; McAdam-Marx C
    J Manag Care Spec Pharm; 2017 Mar; 23(3):267-275. PubMed ID: 28230449
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Baseline and 1-year interim follow-up assessment of Japanese patients initiating insulin therapy who were enrolled in the cardiovascular risk evaluation in people with type 2 diabetes on insulin therapy study: an international, multicenter, observational study.
    Kawamori R; Node K; Hanafusa T; Atsumi Y; Naito Y; Oka Y
    Cardiovasc Diabetol; 2013 Sep; 12():131. PubMed ID: 24011395
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Correlation between plasma glucose and hemoglobin A1c in HIV-infected individuals receiving zidovudine and non-zidovudine containing antiretroviral therapy regimens.
    Saetang T; Sriphrapradang C; Phuphuakrat A; Sungkanuparph S
    HIV Res Clin Pract; 2020; 21(2-3):56-62. PubMed ID: 32431248
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Glycated haemoglobin in diabetic women with and without HIV infection: data from the Women's Interagency HIV Study.
    Glesby MJ; Hoover DR; Shi Q; Danoff A; Howard A; Tien P; Merenstein D; Cohen M; Golub E; Dehovitz J; Nowicki M; Anastos K
    Antivir Ther; 2010; 15(4):571-7. PubMed ID: 20587850
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Competact, a fixed combination of pioglitazone and metformin, improves metabolic markers in type 2 diabetes patients with insufficient glycemic control by metformin alone--results from a post-marketing surveillance trial under daily routine conditions.
    Schöndorf T; Karagiannis E; Posseldt RE; Forst T; Pfützner A
    Diabetes Technol Ther; 2009 Jun; 11(6):379-83. PubMed ID: 19459767
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Predictors of glycaemic control among HIV-positive veterans with diabetes.
    Davies ML; Johnson MD; Brown JN; Bryan WE; Townsend ML
    Int J STD AIDS; 2015 Mar; 26(4):262-7. PubMed ID: 24828555
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Triglyceride/HDL Ratio and Triglyceride Glucose Index as Predictors of Glycemic Control in Patients with Diabetes Mellitus Type 2.
    Babic N; Valjevac A; Zaciragic A; Avdagic N; Zukic S; Hasic S
    Med Arch; 2019 Jun; 73(3):163-168. PubMed ID: 31404127
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Demographic and Clinical Profiles of Type 2 Diabetes Mellitus Patients Initiating Canagliflozin Versus DPP-4 Inhibitors in a Large U.S. Managed Care Population.
    Grabner M; Peng X; Geremakis C; Bae J
    J Manag Care Spec Pharm; 2015 Dec; 21(12):1204-12. PubMed ID: 26679969
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Favorable pleiotropic effects of sodium glucose cotransporter 2 inhibitors: head-to-head comparisons with dipeptidyl peptidase-4 inhibitors in type 2 diabetes patients.
    Shao SC; Chang KC; Lin SJ; Chien RN; Hung MJ; Chan YY; Kao Yang YH; Lai EC
    Cardiovasc Diabetol; 2020 Feb; 19(1):17. PubMed ID: 32050968
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The impact of flash glucose monitoring on glycated hemoglobin in type 2 diabetes managed with basal insulin in Canada: A retrospective real-world chart review study.
    Elliott T; Beca S; Beharry R; Tsoukas MA; Zarruk A; Abitbol A
    Diab Vasc Dis Res; 2021; 18(4):14791641211021374. PubMed ID: 34275385
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Starting insulin therapy in patients with type 2 diabetes: effectiveness, complications, and resource utilization.
    Hayward RA; Manning WG; Kaplan SH; Wagner EH; Greenfield S
    JAMA; 1997 Nov; 278(20):1663-9. PubMed ID: 9388085
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Glycemic Control Outcomes After Canagliflozin Initiation: Observations in a Medicare and Commercial Managed Care Population in Clinical Practice.
    Bailey RA; Schwab P; Xu Y; Pasquale M; Renda A
    Clin Ther; 2016 Sep; 38(9):2046-2057.e2. PubMed ID: 27567160
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inappropriately low glycated hemoglobin values and hemolysis in HIV-infected patients.
    Diop ME; Bastard JP; Meunier N; Thévenet S; Maachi M; Capeau J; Pialoux G; Vigouroux C
    AIDS Res Hum Retroviruses; 2006 Dec; 22(12):1242-7. PubMed ID: 17209766
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Real-world Canagliflozin Utilization: Glycemic Control Among Patients With Type 2 Diabetes Mellitus-A Multi-Database Synthesis.
    Chow W; Miyasato G; Kokkotos FK; Bailey RA; Buysman EK; Henk HJ
    Clin Ther; 2016 Sep; 38(9):2071-82. PubMed ID: 27596020
    [TBL] [Abstract][Full Text] [Related]  

  • 19. An investigation into the durability of glycemic control in patients with type II diabetes initiated on canagliflozin or sitagliptin: A real-world analysis of electronic medical records.
    Wysham CH; Lefebvre P; Pilon D; Lafeuille MH; Emond B; Kamstra R; Pfeifer M; Duh MS; Ingham M
    J Diabetes Complications; 2019 Feb; 33(2):140-147. PubMed ID: 30554838
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Outcomes and treatment patterns of adding a third agent to 2 OADs in patients with type 2 diabetes.
    Levin PA; Wei W; Zhou S; Xie L; Baser O
    J Manag Care Spec Pharm; 2014 May; 20(5):501-12. PubMed ID: 24761822
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.